이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pacira BioSciences 과거 수익 실적

과거 기준 확인 3/6

Pacira BioSciences은 연평균 0.03%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 감소했으며, 연간 0.4%였습니다. 매출은 연평균 14.1%의 비율로 증가했습니다. Pacira BioSciences의 자기자본이익률은 7.9%이고 순이익률은 10.3%입니다.

주요 정보

0.03%

수익 성장률

-1.1%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	14.1%
자기자본 수익률	7.9%
순이익	10.3%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Jun 07

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well

Apr 04

Pacira BioSciences: Higher Prices On The Horizon

Dec 20

Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects

Nov 29

Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly

Oct 15

수익 및 비용 분석

Pacira BioSciences 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqGS:PCRX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	682	70	271	0
31 Dec 23	675	42	269	0
30 Sep 23	666	7	268	0
30 Jun 23	669	-5	261	0
31 Mar 23	669	-10	261	0
31 Dec 22	667	16	255	0
30 Sep 22	654	21	243	0
30 Jun 22	614	39	229	0
31 Mar 22	580	38	215	0
31 Dec 21	542	42	199	0
30 Sep 21	513	62	200	0
30 Jun 21	503	174	205	0
31 Mar 21	443	148	197	0
31 Dec 20	430	146	194	0
30 Sep 20	421	126	197	0
30 Jun 20	408	-10	195	0
31 Mar 20	435	0	200	0
31 Dec 19	421	-11	201	0
30 Sep 19	394	2	191	0
30 Jun 19	372	8	185	0
31 Mar 19	354	7	180	0
31 Dec 18	337	0	177	0
30 Sep 18	321	-4	172	0
30 Jun 18	305	-11	168	0
31 Mar 18	292	-33	164	0
31 Dec 17	287	-43	161	0
30 Sep 17	280	-51	157	0
30 Jun 17	281	-66	153	0
31 Mar 17	280	-54	157	0
31 Dec 16	276	-38	153	0
30 Sep 16	273	-36	155	0
30 Jun 16	267	-11	154	0
31 Mar 16	256	-3	146	0
31 Dec 15	249	2	139	0
30 Sep 15	241	10	133	0
30 Jun 15	231	4	125	0
31 Mar 15	219	-1	116	0
31 Dec 14	198	-14	107	0
30 Sep 14	169	-31	96	0
30 Jun 14	141	-43	83	0
31 Mar 14	111	-52	72	0
31 Dec 13	86	-64	63	22
30 Sep 13	62	-68	56	0
30 Jun 13	48	-69	52	0

양질의 수익: PCRX 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: PCRX 는) 과거에 수익을 냈습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: PCRX 의 수입은 지난 5년 동안 매년 0.03% 씩 증가했습니다.

성장 가속화: PCRX 지난해 흑자를 기록해 5년 평균과 비교하기 어려운 수익 성장률을 보이고 있습니다.

수익 대 산업: PCRX 작년에 수익을 올렸기 때문에 지난 해 수익 성장을 Pharmaceuticals 업계( 19.9% )와 비교하기가 어렵습니다.

Pacira BioSciences 과거 수익 실적

과거 기준 확인 3/6

주요 정보

최근 과거 실적 업데이트

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Investor sentiment improves as stock rises 16%

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Pacira BioSciences records 17.7% sequential growth in August revenue

Pacira Biosciences, Inc. Announces Positive Topline Data from Phase 3 Study of EXPAREL as A Single-Dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty

Pacira BioSciences provides update on July product sales

Pacira BioSciences Q2 2022 Earnings Preview

Pacira BioSciences, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Pacira Biosciences, Inc. Not to Provide Revenue Guidance for the Fiscal Year 2022

Pacira BioSciences sees Q2 revenue below consensus

Chief Clinical Officer recently sold US$53k worth of stock

Chief Technical Officer exercised options to buy US$322k worth of stock.

Investor sentiment deteriorated over the past week

Chairman & CEO recently sold US$734k worth of stock

Chief Clinical Officer exercised options to buy US$129k worth of stock.

Independent Director recently sold US$59k worth of stock

Consensus EPS estimates fall by 28%

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind